Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Chemotherapy, Adjuvant
/ adverse effects
Colonic Neoplasms
/ drug therapy
Disease-Free Survival
Female
Fluorouracil
/ adverse effects
Humans
Japan
Leucovorin
/ adverse effects
Male
Middle Aged
Organoplatinum Compounds
/ adverse effects
Oxaliplatin
/ administration & dosage
Prognosis
Splenic Diseases
/ chemically induced
Colorectal cancer
Oxaliplatin
Sinusoidal obstruction syndrome
Splenic volume
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
22
04
2020
accepted:
02
08
2020
pubmed:
14
8
2020
medline:
15
1
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Chemotherapy with oxaliplatin is known to induce sinusoidal obstruction syndrome (SOS). In a previous single-center study, we reported that oxaliplatin-induced increase in splenic volume (SV) is strongly indicative of SOS, and that this increase in SV persisted for > 1 year after completing chemotherapy. The aim of this study was to confirm the oxaliplatin-induced SV change in a multicenter study in patients with stage III colon cancer in Japan. We enrolled 59 patients who underwent curative resection for stage III colon cancer in the FACOS study in a phase II multi-center clinical study. Participants received mFOLFOX6 or CAPOX as adjuvant chemotherapy. SV change was assessed three times by computed tomographic volumetry: before surgery, on completion of adjuvant chemotherapy, and 1 year after completing adjuvant chemotherapy. SV on completing and 1 year after chemotherapy was significantly higher than that before surgery (P < 0.001). Oxaliplatin-induced SOS persisted for > 1 year after the completion of adjuvant chemotherapy in half of the patients. There was no difference in 3-year disease-free survival with respect to the presence or absence of increased SV. An increase in SV was observed in 72% of patients treated with mFOLFOX6 and 94% of patients treated with CAPOX (P = 0.13). This study can be verified the findings observed in our previous single-center study, oxaliplatin-based adjuvant chemotherapy was associated with an increase in SV. Furthermore, this increase can persist for > 1 year. The continuous presence of SOS may have a negative impact on prognosis in patients that develop recurrent disease.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy with oxaliplatin is known to induce sinusoidal obstruction syndrome (SOS). In a previous single-center study, we reported that oxaliplatin-induced increase in splenic volume (SV) is strongly indicative of SOS, and that this increase in SV persisted for > 1 year after completing chemotherapy. The aim of this study was to confirm the oxaliplatin-induced SV change in a multicenter study in patients with stage III colon cancer in Japan.
METHODS
METHODS
We enrolled 59 patients who underwent curative resection for stage III colon cancer in the FACOS study in a phase II multi-center clinical study. Participants received mFOLFOX6 or CAPOX as adjuvant chemotherapy. SV change was assessed three times by computed tomographic volumetry: before surgery, on completion of adjuvant chemotherapy, and 1 year after completing adjuvant chemotherapy.
RESULTS
RESULTS
SV on completing and 1 year after chemotherapy was significantly higher than that before surgery (P < 0.001). Oxaliplatin-induced SOS persisted for > 1 year after the completion of adjuvant chemotherapy in half of the patients. There was no difference in 3-year disease-free survival with respect to the presence or absence of increased SV. An increase in SV was observed in 72% of patients treated with mFOLFOX6 and 94% of patients treated with CAPOX (P = 0.13).
CONCLUSION
CONCLUSIONS
This study can be verified the findings observed in our previous single-center study, oxaliplatin-based adjuvant chemotherapy was associated with an increase in SV. Furthermore, this increase can persist for > 1 year. The continuous presence of SOS may have a negative impact on prognosis in patients that develop recurrent disease.
Identifiants
pubmed: 32785799
doi: 10.1007/s10147-020-01763-1
pii: 10.1007/s10147-020-01763-1
doi:
Substances chimiques
Organoplatinum Compounds
0
Oxaliplatin
04ZR38536J
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2075-2082Références
Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318
doi: 10.1097/00000658-199909000-00004
Schmoll HJ, Twelves C, Sun W et al (2014) Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 15:1481–1492
doi: 10.1016/S1470-2045(14)70486-3
Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466
doi: 10.1093/annonc/mdh095
Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549–2555
doi: 10.1200/JCO.2009.27.5701
Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016
doi: 10.1016/S0140-6736(08)60455-9
Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983–4990
doi: 10.1200/JCO.2006.05.8156
Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124
doi: 10.1097/SLA.0b013e31815774de
Ward J, Guthrie JA, Sheridan MB et al (2008) Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26:4304–4310
doi: 10.1200/JCO.2008.16.1893
O’Rourke TR, Welsh FKS, Tekkis PP et al (2009) Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol 35:1085–1091
doi: 10.1016/j.ejso.2009.01.015
Imai K, Emi Y, Beppu T et al (2014) Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 40:559–566
doi: 10.1016/j.ejso.2013.12.009
Iwai T, Yamada T, Koizumi M et al (2017) Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. J Surg Oncol 116:947–953
doi: 10.1002/jso.24756
Kosugi C, Koda K, Ishibashi K et al (2018) Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study). Int J Colorectal Dis 33:809–817
doi: 10.1007/s00384-018-2979-9
Yoshimatsu K, Ishibashi K, Koda K et al (2019) A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy. Surg Today 49:498–506
doi: 10.1007/s00595-019-1771-y
Angitapalli R, Litwin AM, Kumar PRG et al (2009) Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 76:363–368
doi: 10.1159/000210025
Jung EJ, Ryu CG, Kim G et al (2012) Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res 32:3357–3362
pubmed: 22843915
El Chediak A, Haydar AA, Hakim A et al (2018) Increase in spleen volume as a predictor of oxaliplatin toxicity. Ther Clin Risk Manag 14:653–657
doi: 10.2147/TCRM.S150968
Vreuls CP, Van Den Broek MA, Winstanley A et al (2012) Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology 61:314–318
doi: 10.1111/j.1365-2559.2012.04208.x
Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177–1188
doi: 10.1056/NEJMoa1713709
Guo Y, Xiong BH, Zhang T et al (2016) XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest 34:94–104
doi: 10.3109/07357907.2015.1104689
Kim MJ, Han SW, Lee DW et al (2016) Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Res Treat 48:990–997
doi: 10.4143/crt.2015.296